Scynexis (SCYX) Current Leases (2019 - 2026)
Scynexis' (SCYX) quarterly Current Leases came in at $526000.0 in Q2 2026, up 18.47% on a YoY basis from $444000.0 in Q2 2025, and up 4.37% quarter-over-quarter from $504000.0 in Q1 2026.
Analysis
Scynexis (SCYX) Current Leases (2019 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Current Leases for 8 consecutive years, with $526000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Leases rose 18.47% year-over-year to $526000.0; the trailing twelve-month figure through Jun 2026 stood at $526000.0 (up 18.47% YoY), and the FY2025 full-year result was $483000.0, up 18.67% from the prior year.
- Current Leases rose to $526000.0 in Q2 2026 per SCYX's latest filing, from $504000.0 in the prior quarter.
- Across five years, Current Leases topped out at $526000.0 in Q2 2026 and bottomed at $77000.0 in Q1 2022.
- Historically, Current Leases has averaged $359277.8 across 5 years, with a median of $364000.0 in 2024.
- The sharpest annual moves came in 2022 and 2026: Current Leases jumped 313.85% in 2022, then grew 18.47% in 2026.
- Over 5 years, Current Leases stood at $282000.0 in 2022, then gained by 20.57% to $340000.0 in 2023, then advanced by 19.71% to $407000.0 in 2024, then gained by 18.67% to $483000.0 in 2025, then rose by 8.9% to $526000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $526000.0, $504000.0, and $483000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 12.38 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 526,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 526,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 463,000.00 |
| Jun 30, 2025 | 444,000.00 |
| Mar 31, 2025 | 425,000.00 |
| Dec 31, 2024 | 407,000.00 |
| Sep 30, 2024 | 389,000.00 |
| Jun 30, 2024 | 372,000.00 |
| Mar 31, 2024 | 356,000.00 |
| Dec 31, 2023 | 340,000.00 |
| Sep 30, 2023 | 325,000.00 |
| Jun 30, 2023 | 310,000.00 |
| Mar 31, 2023 | 296,000.00 |
| Dec 31, 2022 | 282,000.00 |
| Sep 30, 2022 | 269,000.00 |
| Jun 30, 2022 | 199,000.00 |
| Mar 31, 2022 | 77,000.00 |
| Dec 31, 2021 | 70,000.00 |
| Sep 30, 2021 | 65,000.00 |